Through an agreement with the NHS and Sobi UK, people living with haemophilia A in the UK will have increased access to Elocta following a successful bid in the UK’s Haemophilia A Tender
News
EC clears new class of anaemia therapy
BMS’ Reblozyl is the first and only erythroid maturation agent approved in the EU
Eight medicines leap towards EU approval
The recommendations include a conditional approval for Gilead’s Veklury (remdesivir) for COVID-19
MSD’s Keytruda bags approval for new skin cancer indication
In trials Keytruda showed ‘meaningful efficacy’ with an objective response rate of 34%
NICE sticks to Zytiga rejection
Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer would have been eligible for treatment with the drug
NIHR/MRC fund new study of potential genetic roots of ME
The £3.2-million study will investigate whether there are any genetic causes of ME
NICE rejects Novartis’ Mayzent for secondary progressive MS
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
CHMP backs approval of remdesivir as COVID-19 treatment
The drug is the first to be recommended as a treatment for the virus in the EU
Breztri Aerosphere cut rate of COPD exacerbations in PhIII trial
The triple therapy is currently under review for COPD in both the EU and US
New consortium will monitor safety/efficacy of COVID-19 vaccines
The move provides the opportunity to conduct essential post-marketing surveillance
Imperial COVID-19 vaccine begins human testing
The trial will see around 300 people given the vaccine plus a booster shot up to four weeks after the first dose
Kymab wins Supreme Court case against Regeneron
The ‘landmark’ decision invalidates Regeneron’s patent claims covering its genetically modified mice
NICE green light for Roche’s Rozlytrek
The drug targets all solid tumours with the NTRK gene fusions
Tech talent drawn to pharma during COVID-19 pandemic
83% of tech professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago, shows new research by Novartis
New £1.3m national research programme to evaluate coronavirus tests
The multicentre programme will evaluate new tests in hospitals, GP surgeries and care homes around the country
